Viloxazine

Routes
Oral (PO)
Half-Life (t½)
PO: 7h
Formula
C13H19NO3
Molecular Weight
237.3 g/mol
PubChem CID
5666
Aliases
Qelbree

Pharmacological Mechanism

Selective NET inhibition + 5-HT2C agonism + 5-HT2B antagonism. Non-stimulant ADHD treatment approved 2021 (originally marketed in Europe as antidepressant 1970s-2002). No abuse potential.

Half-Life & Elimination Curve (PO: 7h)

100%50%25%12.5%0%0h0×t½7h1×t½14h2×t½21h3×t½28h4×t½35h5×t½0×t½ (0h): 100% remaining (~1.46 mg/L)1×t½ (7h): 50% remaining (~0.731 mg/L)2×t½ (14h): 25% remaining (~0.365 mg/L)3×t½ (21h): 12.5% remaining (~0.183 mg/L)4×t½ (28h): 6.3% remaining (~91.4 µg/L)5×t½ (35h): 3.1% remaining (~45.7 µg/L)
Plasma (PO)t½ Decay (7h)
  • 0×t½0h100% (1.46 mg/L)
  • 1×t½7h50% (0.731 mg/L)
  • 2×t½14h25% (0.365 mg/L)
  • 3×t½21h12.5% (0.183 mg/L)
  • 4×t½28h6.3% (91.4 µg/L)
  • 5×t½35h3.1% (45.7 µg/L)
Elimination t½7h (PO)
Rate Constant (ke)0.099 h⁻¹
Time to Peak (Tmax)5h
Est. Peak (Cmax)1.46 mg/L
Clearance (CL)9.7 L/h
97% Washout (5×t½)35h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References